{
  "total_drugs": 13023,
  "launched_drugs": 0,
  "phase_distribution": {
    "Unknown": 13023
  },
  "indication_distribution": {
    "Cancer": 588,
    "Advanced solid tumor": 543,
    "Solid tumor": 428,
    "Coronavirus disease 19 infection": 392,
    "Metastatic non small cell lung cancer": 381,
    "Metastatic breast cancer": 351,
    "Non-small-cell lung cancer": 346,
    "Metastatic colorectal cancer": 298,
    "Non-insulin dependent diabetes": 272,
    "Breast tumor": 261,
    "Ovary tumor": 259,
    "Rheumatoid arthritis": 242,
    "Squamous cell carcinoma": 229,
    "Pancreas tumor": 227,
    "Hypertension": 224,
    "Glioblastoma": 216,
    "Triple-negative breast cancer": 215,
    "Hepatitis B virus infection": 206,
    "Pain": 205,
    "Multiple myeloma": 200
  },
  "company_distribution": {
    "Pfizer Inc": 191,
    "GSK plc": 160,
    "Novartis AG": 154,
    "Sanofi SA": 146,
    "Takeda Pharmaceutical Co Ltd": 133,
    "AbbVie Inc": 133,
    "Merck & Co Inc": 112,
    "AstraZeneca plc": 97,
    "Bristol Myers Squibb Co": 95,
    "Roche Holding Ltd": 85,
    "Eli Lilly & Co": 71,
    "Bayer AG": 71,
    "Daiichi Sankyo Co Ltd": 69,
    "Astellas Pharma Inc": 64,
    "Johnson & Johnson": 62,
    "Boehringer Ingelheim International GmbH": 59,
    "Seqirus Inc": 58,
    "Chugai Pharmaceutical Co Ltd": 57,
    "Bausch Health Companies Inc": 57,
    "Eisai Co Ltd": 55
  }
}